"March 12, 2010 -- SSRI antidepressants raise the risk of cataracts by about 15% -- enough to cause 22,000 extra cataract cases in the U.S. each year, Canadian researchers suggest.
The study does not prove that antidepressants cause cat"...
Obsessive Compulsive Disorder
LUVOX CR Capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV. Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning.
The efficacy of LUVOX CR Capsules was demonstrated in one 12-week trial in adults with LUVOX CR Capsules as well as in two 10-week trials in adults and in one 10-week trial in children and adolescents (ages 8-17 years) with immediate-release fluvoxamine tablets in outpatients with the diagnosis of OCD as defined in DSM-IV or DSM-III-R (see Clinical Studies).
The efficacy of fluvoxamine for long-term use was established in one maintenance study in adults with immediate-release fluvoxamine tablets (see Clinical Studies). The health care provider who elects to prescribe LUVOX CR Capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
DOSAGE AND ADMINISTRATION
OCD (Obsessive Compulsive Disorder)
The recommended starting dose is 100 mg at bedtime, with weekly increases of 50 mg as tolerated to maximum therapeutic benefit, not to exceed 300 mg per day.
Capsules should not be crushed or chewed.
Pediatric Patients Naοve To Fluvoxamine Maleate
Physicians should consider that the lowest available dose of LUVOX CR Capsules may not be appropriate for pediatric patients naοve to fluvoxamine maleate.
Dosage For Elderly Or Hepatically Impaired Patients
Elderly patients and those with hepatic impairment have been observed to have a decreased clearance of fluvoxamine maleate. Consequently, it may be appropriate to titrate slowly following the initial dose of 100 mg in these patient groups.
Maintenance/Continuation Of Extended Treatment
Although the efficacy of LUVOX CR Capsules beyond 12 weeks of dosing has not been documented in controlled trials, OCD is a chronic condition, and it is reasonable to consider continuation for a responding patient. The benefit of maintaining patients with OCD on immediate-release fluvoxamine maleate tablets after achieving a response for an average duration of about 4 weeks in a 10-week single-blind phase during which patients were titrated to effect was demonstrated in a controlled trial (see Clinical Trials). Dosage adjustments should be made to maintain the patient on the lowest effective dosage, and patients should be periodically reassessed to determine the need for continued treatment.
Switching A Patient To Or From A Monoamine Oxidase Inhibitor (MAOI) Intended To Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with LUVOX CR Capsules. Conversely, at least 14 days should be allowed after stopping LUVOX CR Capsules before starting an MAOI intended to treat psychiatric disorders (see CONTRAINDICATIONS).
Use Of LUVOX CR Capsules With Other MAOIs Such As Linezolid Or Methylene Blue
Do not start LUVOX CR Capsules in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered (see CONTRAINDICATIONS).
In some cases, a patient already receiving LUVOX CR therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, LUVOX CR should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for two weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with LUVOX CR may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS AND PRECAUTIONS).
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with LUVOX CR is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see WARNINGS AND PRECAUTIONS).
Discontinuation Of Treatment With LUVOX CR Capsules
Symptoms associated with discontinuation of other SSRIs or SNRIs have been reported (see WARNINGS AND PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the health care provider may continue decreasing the dose but at a more gradual rate.
Dosage Forms And Strengths
LUVOX CR Capsules are available as:
100 mg Extended-Release Capsules: a two-piece gelatin capsule (dark blue opaque cap/white opaque body) imprinted with logo on one side of the cap and LCR 100 on the other side of the cap. 150 mg Extended-Release Capsules: a two-piece gelatin capsule (dark blue opaque cap/powder blue opaque body) imprinted with logo on one side of the cap and LCR 150 on the other side of the cap.
Storage And Handling
LUVOX CR Capsules are available in the following strengths, colors, imprints, and presentations:
100 mg Extended-Release Capsules: Available in a two-piece gelatin capsule (dark blue opaque cap/white opaque body) imprinted with on one side of the cap and LCR 100 on the other side of the cap. Bottles of 30 ..NDC 68727-600-01
150 mg Extended-Release Capsules: Available in a two-piece gelatin capsule (dark blue opaque cap/powder blue opaque body) imprinted with on one side of the cap and LCR 150 on the other side of the cap. Bottles of 30 ..NDC 68727-601-01
Keep out of reach of children.
LUVOX CR Capsules should be protected from high humidity and stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].
Avoid exposure to temperatures above 30°C (86°F).
Dispense in tight containers.
Distributed by Jazz Pharmaceuticals, Inc. Palo Alto CA 94304. Revised July 2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/3/2017
Additional Luvox CR Information
Luvox CR - User Reviews
Luvox CR User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.